We are proud and honored to introduce the FLASHKNiFE Consortium, supported by the European Institute of Innovation & Technology for Health (EIT Health).
More than 10 million patients receive radiation therapy each year worldwide, making it an essential tool for cancer treatment, along with surgery and chemotherapy. Moreover, 30% to 40% of treated patients are resistant to radiotherapy. Radiation-induced side effects severely limit the radiation dose given to the tumor. If toxicity could be reduced, a greater dose of radiation could be given, providing a more efficient and better tolerated outcome in cancer treatment.
Our mission: achieve the translation of FLASH radiation therapy to clinical use and provide more efficient treatments to patients, with less side effects.
Read more below.